Complication rates of CT-guided transthoracic lung biopsy: meta-analysis
Wouter J. Heerink,G. H. de Bock,G. J. de Jonge,Harry J.M. Groen,Rozemarijn Vliegenthart,Matthijs Oudkerk +5 more
Reads0
Chats0
TLDR
In CT-guided lung biopsy, minor complications were common and occurred more often in core biopsy than FNA, and major complication rate was low.Abstract:
To meta-analyze complication rate in computed tomography (CT)-guided transthoracic lung biopsy and associated risk factors. Four databases were searched from 1/2000 to 8/2015 for studies reporting complications in CT-guided lung biopsy. Overall and major complication rates were pooled and compared between core biopsy and fine needle aspiration (FNA) using the random-effects model. Risk factors for complications in core biopsy and FNA were identified in meta-regression analysis. For core biopsy, 32 articles (8,133 procedures) were included and for FNA, 17 (4,620 procedures). Pooled overall complication rates for core biopsy and FNA were 38.8 % (95 % CI: 34.3–43.5 %) and 24.0 % (95 % CI: 18.2–30.8 %), respectively. Major complication rates were 5.7 % (95 % CI: 4.4–7.4 %) and 4.4 % (95 % CI: 2.7–7.0 %), respectively. Overall complication rate was higher for core biopsy compared to FNA (p < 0.001). For FNA, larger needle diameter was a risk factor for overall complications, and increased traversed lung parenchyma and smaller lesion size were risk factors for major complications. For core biopsy, no significant risk factors were identified. In CT-guided lung biopsy, minor complications were common and occurred more often in core biopsy than FNA. Major complication rate was low. For FNA, smaller nodule diameter, larger needle diameter and increased traversed lung parenchyma were risk factors for complications. • Minor complications are common in CT-guided lung biopsy
• Major complication rate is low in CT-guided lung biopsy
• CT-guided lung biopsy complications occur more often in core biopsy than FNA
• Major complication rate is similar in core biopsy and FNA
• Risk factors for FNA are larger needle diameter, smaller lesion sizeread more
Citations
More filters
Journal ArticleDOI
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo,Philip C. Mack,Giorgio V. Scagliotti,Paul Baas,Fabrice Barlesi,Trever G. Bivona,Roy S. Herbst,Tony Mok,Nir Peled,Robert Pirker,Luis E. Raez,Martin Reck,Jonathan W. Riess,Lecia V. Sequist,Frances A. Shepherd,Lynette M. Sholl,Daniel Shao-Weng Tan,Heather A. Wakelee,Ignacio I. Wistuba,Murry W. Wynes,David P. Carbone,Fred R. Hirsch,David R. Gandara +22 more
TL;DR: It is concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.
Journal ArticleDOI
Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study
Erik Folch,Michael A. Pritchett,Michael Nead,Mark R. Bowling,Septimiu Murgu,William S. Krimsky,Boris A. Murillo,Gregory P. LeMense,Douglas J. Minnich,Douglas J. Minnich,Sandeep Bansal,Blesilda Q. Ellis,Amit K. Mahajan,Thomas R. Gildea,Rabih Bechara,Eric Sztejman,Javier Flandes,Otis B. Rickman,Sadia Benzaquen,D. Kyle Hogarth,Philip A. Linden,Momen M. Wahidi,Jennifer S. Mattingley,Kristin L. Hood,Haiying Lin,Jennifer J. Wolvers,Sandeep J. Khandhar,Carlos Anciano,Alejandro Aragaki,Douglas A. Arenberg,Omar Awais,Ricardo Balestra,Emanuela Barisione,Rabih Bechara,Michela Bezzi,Krishnendu Bhadra,Julio Bird,Alessandro Blanco,Mark R. Bowling,Robert J. Cerfolio,Merete Christensen,Joseph Cicenia,Antony Courey,John Doty,Kevin Eggleston,Blesilda Ellis,Iker Fernandez,Erik Folch,Alexandre Furman,George David Gass,Thomas Gildea,Anil Gogineni,Musija Fikreta Grabcanovic,John Hinze,David Kyle Hogarth,Raj Karunakara,Jordan Kazakov,Sandeep Khandhar,Sandhya Khurana,William Krimsky,Ganesh Krishna,Roman Krol,Roland Kropfmüller,Bernd Lamprecht,Kelvin Lau,Andrew Lee,Gregory P. LeMense,P. Linden,Peter O. Lutz,Amit Mahajan,Kamran Mahmood,Fabien Maldonado,Rafael Martinez,Jennifer Mattingley,Douglas J. Minnich,Septimiu Murgu,Boris Murillo,Katie Nason,Michael Nead,Christopher Parks,Kenneth Perret,P. Porsch,Michael Pritchett,Otis Rickman,Maydee Rosario,Mario Salio,Saiyad Sarkar,Andrew Seevaratnam,Sonali Sethi,Jaspal Singh,Michael Studnicka,Tamejiro Takubo,Catalina Teba,Christopher Towe,Marco Trigiani,JeanRichel Vergnon,Niels-Erik Viby,Momen Wahidi,Ernest Waller,Benjamin Wei,Dragos Zanchi,Michael Zgoda +101 more
TL;DR: In this paper, a prospective, multicenter, cohort study that evaluated electromagnetic navigation bronchoscopy (ENB) using the superDimension navigation system (Medtronic, Minneapolis, Minnesota) is presented.
Journal ArticleDOI
CIRSE Guidelines on Percutaneous Needle Biopsy (PNB)
TL;DR: Complications are stratified on the basis of their outcome (see “Appendix”) and major complications result in hospital admittance or prolonged hospitalization, unplanned increase in level of cares, permanent sequelae or death.
Journal ArticleDOI
Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis.
Erik Folch,Gonzalo Labarca,Daniel Ospina-Delgado,Fayez Kheir,Adnan Majid,Sandeep J. Khandhar,Hiren J. Mehta,Michael A. Jantz,Sebastian Fernandez-Bussy +8 more
TL;DR: ENB is very safe with good sensitivity for diagnosing malignancy in patients with PPL, and the applicability of the findings is limited as the majority of studies were done with the superDimension navigation system and heterogeneity was high.
Journal ArticleDOI
Exosomes: a new horizon in lung cancer.
TL;DR: An overview of the biology and function of exosomes and exosome miRNAs as indicators of diagnosis and treatment response in lung cancer is presented and preliminary data onExosomes as potential therapeutic agents are reported.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
TL;DR: The Newcastle-Ottawa Scale (NOS) as discussed by the authors was developed to assess the quality of nonrandomised studies with its design, content and ease of use directed to the task of incorporating the quality assessments in the interpretation of meta-analytic results.